Pfizer standalone net profit declines 28.57% in the June 2017 quarter

Image
Capital Market
Last Updated : Jul 31 2017 | 12:04 AM IST

Sales decline 16.02% to Rs 420.91 crore

Net profit of Pfizer declined 28.57% to Rs 57.17 crore in the quarter ended June 2017 as against Rs 80.04 crore during the previous quarter ended June 2016. Sales declined 16.02% to Rs 420.91 crore in the quarter ended June 2017 as against Rs 501.23 crore during the previous quarter ended June 2016. ParticularsQuarter EndedJun. 2017Jun. 2016% Var.Sales420.91501.23 -16 OPM %18.2120.17 -PBDT103.75122.23 -15 PBT88.52107.25 -17 NP57.1780.04 -29

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 29 2017 | 5:47 PM IST

Next Story